secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2023-12-13T23:59:59+00:00
Accession:  0000950170-23-069892
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CRISPR amends Vertex collaboration on exa-cel; $20M contingent payment, cost deferral adjustments
--------------------------------------------------------------------------------

- CRISPR agrees to pay Vertex $20M contingent payment upon specified event under Amendment No. 1 for exa-cel.
- Deferral of CRISPR's share of costs capped at $25M annually; amounts offset against future exa-cel profitability.
- Amendment allocates costs from a new third-party license agreement entered by Vertex; some details redacted.
- Changes timing and portion of CRISPR's permitted cost deferrals under certain specified circumstances.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000095017023069892/0000950170-23-069892-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000095017023069892/crsp-20231212.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-069892

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer